Radiation plus targeted pill vs pill alone for EGFR/ALK-NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have non-small cell lung cancer (NSCLC) confirmed by biopsy or pathology report
- Have a tumor mutation in EGFR or ALK/ROS (not negative for these)
- Have been on a targeted TKI pill for about 2–4 months and your cancer has not progressed
- Have limited spread: 1–5 metastatic sites away from the main tumor and nearby lymph nodes
- Be able to safely receive focused radiation to the involved areas and continue the TKI pill
- Have certain blood counts from within 15 days: neutrophils ≥500, platelets ≥50,000, and hemoglobin ≥8.0 (transfusion allowed to reach the number)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial tests if giving radiation to the main lung tumor before starting a targeted therapy pill can help delay the cancer from growing. It is for people with advanced non-small cell lung cancer that has a specific genetic change and who have not had targeted therapy before.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This trial tests whether adding focused radiation therapy to the spots of cancer that remain after your first treatment (an EGFR pill plus chemo) can help control advanced lung cancer better. It is for people whose cancer has an EGFR mutation and who have only a few residual spots, with the goal of delaying progression and improving outcomes.
Hear when a new Oligometastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.